Atopic dermatitis laboratory findings: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(10 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Atopic dermatitis}}
{{Atopic dermatitis}}
{{CMG}}; {{AE}}  
{{CMG}}; {{AE}}{{S.S}}  
 
{{S.S}}  


==Overview==
==Overview==
An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
There diagnosis of atopic dermatitis remains clinical as there is no reliable [[Biomarker|bio-marker]] that can differentiate atopic dermatitis from other [[skin]] [[diseases]].
 
OR
 
Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
 
OR
 
[Test] is usually normal for patients with [disease name].
 
OR
 
Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].
 
OR
 
There are no diagnostic laboratory findings associated with [disease name].


==Laboratory Findings==
==Laboratory Findings==
* There are no reliable diagnostic laboratory findings associated with atopic dermatitis.
*There are no reliable diagnostic laboratory findings associated with atopic dermatitis.
* The most common laborotory finding in atopic dermatitis is an elevated total and/or allergen-specific serum IgE level, which is not present in about 20% of affected individuals
*The most common laborotory finding in atopic dermatitis is an elevated total and/or allergen-specific serum [[IgE]] level, which is not present in about 20% of affected individuals.<ref name="pmid234738562">{{cite journal |vauthors=Kabashima K |title=New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity |journal=J. Dermatol. Sci. |volume=70 |issue=1 |pages=3–11 |date=April 2013 |pmid=23473856 |doi=10.1016/j.jdermsci.2013.02.001 |url=}}</ref>
Th
*Monitoring of [[IgE]] levels is not recommended for the assessment of atopic dermatitis severity.
 
*Higher serum levels of some of the new biomarkers using the [[SCORAD|SCORing Atopic Dermatitis]] ([[SCORAD]]) index and other severity scales:<ref name="pmid170472942">{{cite journal |vauthors=Aral M, Arican O, Gul M, Sasmaz S, Kocturk SA, Kastal U, Ekerbicer HC |title=The relationship between serum levels of total IgE, IL-18, IL-12, IFN-gamma and disease severity in children with atopic dermatitis |journal=Mediators Inflamm. |volume=2006 |issue=4 |pages=73098 |date=2006 |pmid=17047294 |pmc=1618943 |doi=10.1155/MI/2006/73098 |url=}}</ref><ref name="pmid127753632">{{cite journal |vauthors=Di Lorenzo G, Gangemi S, Merendino RA, Minciullo PL, Cannavò SP, Martinelli N, Mansueto P, Rini GB, Corrocher R, Pacor ML |title=Serum levels of soluble CD30 in adult patients affected by atopic dermatitis and its relation to age, duration of disease and Scoring Atopic Dermatitis index |journal=Mediators Inflamm. |volume=12 |issue=2 |pages=123–5 |date=April 2003 |pmid=12775363 |pmc=1781600 |doi=10.1080/0962935031000097736 |url=}}</ref><ref name="pmid20306677">{{cite journal |vauthors=El Mongy S, Metwaly SS, Arafat MS, Hady HA |title=Serum levels of soluble CD30 in patients with atopic dermatitis: correlations with age, disease duration and severity |journal=Egypt J Immunol |volume=15 |issue=1 |pages=123–9 |date=2008 |pmid=20306677 |doi= |url=}}</ref><ref name="pmid21294778">{{cite journal |vauthors=Ezzat MH, Hasan ZE, Shaheen KY |title=Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring |journal=J Eur Acad Dermatol Venereol |volume=25 |issue=3 |pages=334–9 |date=March 2011 |pmid=21294778 |doi=10.1111/j.1468-3083.2010.03794.x |url=}}</ref><ref name="pmid15813816">{{cite journal |vauthors=Jahnz-Rozyk K, Targowski T, Paluchowska E, Owczarek W, Kucharczyk A |title=Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis |journal=Allergy |volume=60 |issue=5 |pages=685–8 |date=May 2005 |pmid=15813816 |doi=10.1111/j.1398-9995.2005.00774.x |url=}}</ref><ref name="pmid18266834">{{cite journal |vauthors=Nakazato J, Kishida M, Kuroiwa R, Fujiwara J, Shimoda M, Shinomiya N |title=Serum levels of Th2 chemokines, CCL17, CCL22, and CCL27, were the important markers of severity in infantile atopic dermatitis |journal=Pediatr Allergy Immunol |volume=19 |issue=7 |pages=605–13 |date=November 2008 |pmid=18266834 |doi=10.1111/j.1399-3038.2007.00692.x |url=}}</ref><ref name="StänderRopper2021">{{cite journal|last1=Ständer|first1=Sonja|last2=Ropper|first2=Allan H.|title=Atopic Dermatitis|journal=New England Journal of Medicine|volume=384|issue=12|year=2021|pages=1136–1143|issn=0028-4793|doi=10.1056/NEJMra2023911}}</ref>
OR
**Serum levels of [[CD30]]
 
**Macrophage-derived chemoattractant (MDC)
An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
**[[Interleukin 12|Interleukins (IL)-12]]
 
**[[Interleukin 16|Interleukins (IL)-16]]
OR
**[[Interleukin 18|Interleukins (IL)-18]]
 
**[[Interleukin 31|Interleukins (IL)-31]]
[Test] is usually normal among patients with [disease name].
**Thymus and activation-regulated [[chemokine]] (TARC)
 
OR
 
Laboratory findings consistent with the diagnosis of [disease name] include:
*[Abnormal test 1]
*[Abnormal test 2]
*[Abnormal test 3]
 
OR
 
Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].
 


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
[[Category:Autoimmune diseases]]
[[Category:Autoimmune diseases]]
[[Category:Dermatology]]
[[Category:Dermatology]]
[[Category:Needs content]]
[[Category:Primary care]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Latest revision as of 03:11, 26 April 2021

Atopic dermatitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Atopic dermatitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Atopic dermatitis laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Atopic dermatitis laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Atopic dermatitis laboratory findings

CDC on Atopic dermatitis laboratory findings

Atopic dermatitis laboratory findings in the news

Blogs onAtopic dermatitis laboratory findings

Directions to Hospitals Treating Atopic dermatitis

Risk calculators and risk factors forAtopic dermatitis laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shalinder Singh, M.B.B.S.[2]

Overview

There diagnosis of atopic dermatitis remains clinical as there is no reliable bio-marker that can differentiate atopic dermatitis from other skin diseases.

Laboratory Findings

References

  1. ↑ Kabashima K (April 2013). "New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity". J. Dermatol. Sci. 70 (1): 3–11. doi:10.1016/j.jdermsci.2013.02.001. PMID 23473856.
  2. ↑ Aral M, Arican O, Gul M, Sasmaz S, Kocturk SA, Kastal U, Ekerbicer HC (2006). "The relationship between serum levels of total IgE, IL-18, IL-12, IFN-gamma and disease severity in children with atopic dermatitis". Mediators Inflamm. 2006 (4): 73098. doi:10.1155/MI/2006/73098. PMC 1618943. PMID 17047294.
  3. ↑ Di Lorenzo G, Gangemi S, Merendino RA, Minciullo PL, Cannavò SP, Martinelli N, Mansueto P, Rini GB, Corrocher R, Pacor ML (April 2003). "Serum levels of soluble CD30 in adult patients affected by atopic dermatitis and its relation to age, duration of disease and Scoring Atopic Dermatitis index". Mediators Inflamm. 12 (2): 123–5. doi:10.1080/0962935031000097736. PMC 1781600. PMID 12775363.
  4. ↑ El Mongy S, Metwaly SS, Arafat MS, Hady HA (2008). "Serum levels of soluble CD30 in patients with atopic dermatitis: correlations with age, disease duration and severity". Egypt J Immunol. 15 (1): 123–9. PMID 20306677.
  5. ↑ Ezzat MH, Hasan ZE, Shaheen KY (March 2011). "Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring". J Eur Acad Dermatol Venereol. 25 (3): 334–9. doi:10.1111/j.1468-3083.2010.03794.x. PMID 21294778.
  6. ↑ Jahnz-Rozyk K, Targowski T, Paluchowska E, Owczarek W, Kucharczyk A (May 2005). "Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis". Allergy. 60 (5): 685–8. doi:10.1111/j.1398-9995.2005.00774.x. PMID 15813816.
  7. ↑ Nakazato J, Kishida M, Kuroiwa R, Fujiwara J, Shimoda M, Shinomiya N (November 2008). "Serum levels of Th2 chemokines, CCL17, CCL22, and CCL27, were the important markers of severity in infantile atopic dermatitis". Pediatr Allergy Immunol. 19 (7): 605–13. doi:10.1111/j.1399-3038.2007.00692.x. PMID 18266834.
  8. ↑ Ständer, Sonja; Ropper, Allan H. (2021). "Atopic Dermatitis". New England Journal of Medicine. 384 (12): 1136–1143. doi:10.1056/NEJMra2023911. ISSN 0028-4793.
Retrieved from "https://www.wikidoc.org/index.php?title=Atopic_dermatitis_laboratory_findings&oldid=1698571"